Raw Data for the article: Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

SARS‐CoV‐2 vaccine is considered the primary health strategy able to end the current COVID‐19 pandemic. This viral infection impacts more severely solid organ transplant recipients (SOTRs) than general population, but the effect of vaccination in this subgroup of immunosuppressed patients is not known due to their exclusion from vaccination trials. Preliminary reports suggest a lower antibody production after BNT162b2 Pfizer/BioNTech mRNA‐vaccine, 1 , 2 , 3 , 4 but no data are currently available on the elicited virus‐specific T cell responses.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗被视为能够终结当前新型冠状病毒肺炎（COVID-19）大流行的首要公共卫生策略。相较于普通人群，该病毒感染对实体器官移植受者（SOTRs）的危害更为严重，但由于这类免疫抑制患者亚组被排除在疫苗临床试验之外，目前尚不清楚疫苗接种在该群体中的效果。初步研究报告显示，接种辉瑞（Pfizer）/生物泰克（BioNTech）开发的BNT162b2信使核糖核酸（mRNA）疫苗后，受试者的抗体生成水平较低[1,2,3,4]，但目前尚无关于该疫苗诱导的病毒特异性T细胞应答的相关数据。